Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Wells

Nurse Practitioner Beachwood, OH Nurse Practitioner

NPI 1760972665 CMS profile 10476617

3690 Orange Pl Ste 250, Beachwood, OH 44122

Open in the dashboard

General payments

$4,550

224 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Wells of Beachwood, OH is reported in the CMS Open Payments database as having received $4,550 across 224 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30 1
2024 General $412 4
2023 General $984 44
2022 General $1,502 84
2021 General $1,623 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Wells
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Michelle Wells were reported at $30. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Michelle Wells Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,623 $135 $40–$426 $132
2022 $1,502 $152 $48–$470 $149
2023 $984 $166 $54–$529 $160
2024 $412 $173 $55–$556 $164
2025 $30 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Biohaven Pharmaceuticals, Inc. $974 17 payments
  2. AbbVie, Inc. $911 40 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $753 46 payments
  4. Scilex Pharmaceuticals Inc. $410 23 payments
  5. Janssen Pharmaceuticals, Inc $406 4 payments
  6. Hikma Pharmaceuticals USA $182 13 payments
  7. GRT US Holding, Inc. $171 6 payments
  8. Pfizer Inc. $160 14 payments
  9. Almatica Pharma LLC $147 45 payments
  10. Otsuka America Pharmaceutical, Inc. $90 1 payment
  11. Other $346 15 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,466 184 payments
  2. Education $84 40 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT Primary Care $1,727 63 payments
  2. UBRELVY $480 28 payments
  3. ZTLido $351 19 payments
  4. INVEGA SUSTENNA $291 3 payments
  5. Qutenza $249 9 payments
  6. VRAYLAR $233 2 payments
  7. QULIPTA $231 11 payments
  8. Kloxxado $182 13 payments
  9. NURTEC ODT Pain $160 14 payments
  10. GRALISE $147 45 payments
  11. Other $1,259 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

83

Median for Nurse Practitioner: 389

Drug cost

$549

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 11 $158
Cyclobenzaprine Hcl Generic 17 $124
Tizanidine Hcl Generic 11 $95
Ibuprofen Generic 13 $94
Topiramate Generic 16 $44
Tramadol Hcl Generic 15 $34

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $233
$233 — —
LYBALVI
  • Alkermes, Inc. $89
$89 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $45
$45 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

224 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record